BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. NASDAQ:PCRX, the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter 2026 financial results after th…
Pacira BioSciences PCRX has announced that UnitedHealthcare, the largest U.S. health insurer with about 40 million members, will reimburse separately for Exparel (bupivacaine liposome injectable suspension), Pacira's non-opioid pain medicine, when used in outpatient settings such as hospital outpat…
Pacira BioSciences PCRX is reshaping its business through an agreement to divest its iovera medical device franchise to Zimmer Biomet ZBH for up to $140 million. The deal marks another step in Pacira's strategy to transition toward an innovative biopharmaceutical company while allowing Zimmer Biome…
Pacira BioSciences Price Target Maintained With a $38.00/Share by HC Wainwright & Co.
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings --BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. NASDAQ:PCRX, the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives o…
Pacira Biosciences Inc NASDAQ:PCRX:
WASHINGTON (dpa-AFX) - Pacira BioSciences Inc. (PCRX) on Tuesday announced an agreement to divest its iovera business to Zimmer Biomet Holdings (ZBH) for up to $140 million.The transaction is expected to close in the third quarter of 2026.The deal includes an upfront payment of $70 million and up t…
By Connor HartPacira BioSciences said it agreed to sell its ioveradeg business to Zimmer Biomet for up to $140 million.The ioveradeg system is drug-free medical device, cleared by the Food and Drug Administration, that relieves pain via cryoneurolysis--a process whereby focused cold therapy is appl…
Pacira BioSciences entered into a Stock and Asset Purchase Agreement to divest its handheld cryoanalgesia devices business, including iovera°, to Zimmer for up to $140 million. The deal includes a $70 million upfront payment, subject to customary adjustments, and up to $70 million in contingent pay…
Pacira BioSciences Also Eligible for Additional $70M in Milestone Payments
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments ---- Two companies will collaborate on advancing the spasticity program ---- Supports 5x30 strategy and advances Pacira’s transition into an inno…
Pacira BioSciences to Get Up to $140M With $70M Upfront for Ioveradeg
Pacira BioSciences Announces Agreement to Divest Its Ioveradeg Business to Zimmer Biomet
